Evaluating PET imaging for gynecological tumors
Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Gynecological Tumors.
This study is testing if advanced PET imaging techniques can help doctors better diagnose and manage gynecological tumors in adult patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 380 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | IRCCS San Raffaele Academic / other |
| Locations | 1 site (Milano, Italia) |
| Trial ID | NCT06159907 on ClinicalTrials.gov |
What this trial studies
This study evaluates the diagnostic and prognostic capabilities of PET imaging techniques, specifically PET/CT and PET/MRI, in patients with gynecological tumors. It focuses on adult patients who have undergone at least one PET scan using 18F-FDG for staging or restaging their cancer. The research aims to enhance the understanding of how these advanced imaging methods can improve the management of gynecological cancers, which include tumors of the cervix, endometrium, ovary, vagina, and vulva. By analyzing clinical and imaging data, the study seeks to provide insights into the effectiveness of these imaging modalities in clinical practice.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients diagnosed with a gynecological oncological disease who have previously undergone PET imaging.
Not a fit: Patients under 18 years old or those without sufficient clinical and imaging data will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic accuracy and treatment planning for patients with gynecological tumors.
How similar studies have performed: Other studies have shown promising results with PET imaging in oncology, suggesting that this approach may yield beneficial insights for gynecological tumors as well.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * adult patients suffering from a gynecological oncological disease; Patients who have performed at least one PET study with 18F FDG for the staging or restaging of their oncological pathology; patients who give written informed consent to the study Exclusion Criteria: * patients \<18 years lack of availability of clinical and PET imaging data useful for analyses.
Where this trial is running
Milano, Italia
- Irccs San Raffaele — Milano, Italia, Italy (Recruiting)
Study contacts
- Study coordinator: Arturo Chiti
- Email: chiti.arturo@hsr.it
- Phone: 0226432716
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.